glp 1 agonists and sglt2 inhibitors combination GLP-1 receptor agonists: a sound SGLT2 inhibitors vs GLP-1 receptor

8,37 Secondary endpoints in STEP-HFpEF DM, including changes in 6-minute walk distance and body weight, also favoured semaglutide

[DOI] [PMC free article] [PubMed] [Google Scholar] 58.Heerspink HJ, Jongs N, Chertow GM, Langkilde AM, McMurray JJ, Correa-Rotter R, et al

By providing invaluable support, guidance, and education, you can help patients rewrite their scripts and achieve a happy, healthy ending

The emerging data on the broad effects of GLP-1 medications may support a more holistic approach to treating diseases that tend to exacerbate with age

These agents have been supported by important clinical trials, including Satiety and Clinical Adipose Liraglutide Evidence (SCALE), Semaglutide Treatment Effect in People with Obesity (STEP) program trials, and Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (44)

Ilyas Z, Perna S, Al-Thawadi S, Alalwan TA, Riva A, Petrangolini G, et al